ELABELA protects against diabetic kidney disease by activating high glucose-inhibited renal tubular autophagy
Xiyin Zheng
Lulu Yin
Jing Song
Juan Chen
Wensha Gu
Min Shi
Hong Zhang
Department of Endocrinology,the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University,Huai'an,Jiangsu 223300,China
摘要：ELABELA(ELA),an endogenous ligand of the apelin receptor(also known as apelin peptide jejunum[APJ]),has been shown to decrease in the plasma of patients with diabetic kidney disease(DKD).In the current study,we explored the potential function as well as the underlying mechanisms of ELA in DKD.We first found that the ELA levels were decreased in the kidneys of DKD mice.Then,we found that ELA administration mitigated renal damage and downregulated the expression of fibronectin,collagen Ⅳ,and transforming growth factor-β1 in the db/db mice and the high glucose cultured HK-2 cells.Furthermore,the autophagy markers,Beclin-1 and LC3-Ⅱ/LC3-Ⅰ ratio,were significantly impaired in DKD,but the ELA treatment reversed these alterations.Mechanistically,the inhibitory effects of ELA on the secretion of fibrosis-associated proteins in high glucose conditions were blocked by pretreatment with 3-methyladenine(an autophagy inhibitor).In summary,these in vivo and in vitro results demonstrate that ELA effectively protects against DKD by activating high glucose-inhibited renal tubular autophagy,potentially serving as a novel therapeutic candidate for DKD.
机标关键词：elabelaglucosekidneyhighactivatingagainstautophagydiabetic
分类号：R587.2(内分泌腺疾病及代谢病)R692.9(泌尿科学（泌尿生殖系疾病）)
论文发表日期：2023-11-30
在线出版日期：2026-03-31（本平台首次上网日期，不代表文献的发表时间）
页数：11( 中插4,460-469 )
英文信息